Literature DB >> 7912734

Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Göteborg, Sweden.

O Samuelsson1, T Hedner, G Berglund, B Persson, O K Andersson, L Wilhelmsen.   

Abstract

The objective of this study was to analyse predictive factors for the development of diabetes mellitus during long-term treatment of hypertension and to compare the diabetogenic potential of thiazide diuretics and non-selective beta-adrenoceptor blockers. The study population comprised 686 hypertensive men, aged 47-54 years, who were followed for 15 years. Patients were treated with either thiazide diuretics or beta-adrenoceptor blockers as monotherapy or in combination with one another or alternative other antihypertensive drugs. During the first part of the study, i.e. during the 1970s, only non-selective beta-adrenoceptor blockers were used. The average yearly incidence of the development of diabetes mellitus during follow-up was 1.3%. In univariate analysis body mass index, serum triglyceride level, radiographic heart enlargement and beta-blocker therapy were significantly associated with the development of diabetes mellitus. Predictors selected by stepwise Cox regression were body mass index, radiological heart enlargement and beta-blocker therapy. Two subgroups with patients treated with nonselective beta-adrenoceptor blockers but not with thiazide diuretics during the first five years of follow-up (the beta-blocker group; n = 93) or with thiazide diuretics but not with nonselective beta-adrenoceptor blockers during the first five years of follow-up (the thiazide-group; n = 96) were identified. The relative risk for developing diabetes mellitus was significantly higher in the beta-blocker group being 6.1 after 10 years and 3.5 after 15 years treatment in comparison with the thiazide group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912734

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  13 in total

Review 1.  The metabolic syndrome and related cardiovascular risk.

Authors:  F Ramos; H P Baglivo; A J Ramírez; R Sánchez
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

Review 2.  Antihypertensive medications and blood sugar: theories and implications.

Authors:  David F Blackburn; Thomas W Wilson
Journal:  Can J Cardiol       Date:  2006-03-01       Impact factor: 5.223

Review 3.  The glycemic effects of antihypertensive medications.

Authors:  Joshua I Barzilay; Barry R Davis; Paul K Whelton
Journal:  Curr Hypertens Rep       Date:  2014-01       Impact factor: 5.369

4.  Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.

Authors:  Joshua I Barzilay; Barry R Davis; Sara L Pressel; Jeffrey A Cutler; Paula T Einhorn; Henry R Black; William C Cushman; Charles E Ford; Karen L Margolis; Jamaluddin Moloo; Suzanne Oparil; Linda B Piller; Debra L Simmons; Mary Ellen Sweeney; Paul K Whelton; Nathan D Wong; Jackson T Wright
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-03-06

Review 5.  Drug-Induced Hyperglycaemia and Diabetes.

Authors:  Neila Fathallah; Raoudha Slim; Sofien Larif; Houssem Hmouda; Chaker Ben Salem
Journal:  Drug Saf       Date:  2015-12       Impact factor: 5.606

Review 6.  The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.

Authors:  A Hameedi; H L Chadow
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

7.  Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome.

Authors:  Melvin R Hayden; James R Sowers
Journal:  J Am Soc Hypertens       Date:  2008-06-02

Review 8.  Differential effects of antihypertensive drugs on new-onset diabetes?

Authors:  William J Elliott
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

9.  Metabolic effects of carvedilol through β-arrestin proteins: investigations in a streptozotocin-induced diabetes rat model and in C2C12 myoblasts.

Authors:  Berna Güven; Zümra Kara; Arzu Onay-Beşikci
Journal:  Br J Pharmacol       Date:  2020-11-15       Impact factor: 8.739

10.  Lack of interaction of beta-cell-function-associated variants with hypertension on change in fasting glucose and diabetes risk: the Framingham Offspring Study.

Authors:  Jose M de Miguel-Yanes; Bianca Porneala; Michael J Pencina; Caroline S Fox; Jose C Florez; David S Siscovick; Josée Dupuis; James B Meigs
Journal:  J Hypertens       Date:  2013-05       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.